PUFAs: Structures, metabolism and functions

Advances in Clinical and Experimental Medicine

Volumn 24, Issue 6, 2015, Pages 931-941

  Wiktorowska Owczarek, Anna ^a   Berezińska, Malgorzata ^a   Nowak, Jerzy Z ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

ARA; DHA; EPA; Polyunsaturated fatty acids

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSANOID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; LINOLENIC ACID; OMEGA 3 FATTY ACID; POLYUNSATURATED FATTY ACID; TRIACYLGLYCEROL; UNSATURATED FATTY ACID;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR EFFECT; CELL MEMBRANE FLUIDITY; CYTOKINE RELEASE; DIET; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; HUMAN; INFLAMMATION; NERVOUS SYSTEM; REVIEW; THROMBOCYTE AGGREGATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DIET SUPPLEMENTATION; DIETARY REFERENCE INTAKE; METABOLISM; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; DIET; DIETARY SUPPLEMENTS; FATTY ACIDS, UNSATURATED; HUMANS; MOLECULAR STRUCTURE; RECOMMENDED DIETARY ALLOWANCES; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84964695162     PISSN: 18995276     EISSN: 24512680     Source Type: Journal    
DOI: 10.17219/acem/31243     Document Type: Review

References (61)

1. Bang HO, Dyerberg DJ, Sinlair HM: The composition of the Eskimo food in north western Greenland. Am J Clin Nutr 1980, 33, 2657-2661.
2. Sinclair HM: Prevention of coronary heart disease: the role of essential fatty acids. Postgrad Med J 1980, 56, 579-584.
3. Das UN: Essentials Fatty Acids -a review. Curr Pharm Biotechnol 2006, 7, 467-482.
4. Nowak JZ: Wielonienasycone kwasy tłuszczowe omega-3 w siatkówce i praktyce medycznej -blaski i cienie. Mag Lek Okul 2009, 3, 208-220.
5. San Giovanni JP, Chew EY: The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res 2005, 24, 87-138.
6. Le HD, Meisel JA, de Meijer VD, Gura KM, Puder M: The essentiality of arachidonic acid and docosahexaenoic acid. Prostaglandins Leukot Essent Fatty Acids 2009, 81, 165-170.
7. Calder PC: n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006, 83, 1505-1519.
8. Simopoulos AP: Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002, 21, 495-505.
9. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S: Stereochemical assignment, anti-inflammatory properties, and receptor for the omega-3 lipid mediator resolving E1. J Exp Med 2005, 201, 713-722.
10. Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN: Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 2007, 178, 3912-3917.
11. Serhan CN, Chiang N: Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol 2008, 153, 200-215.
12. Schwab JM, Serhan CN: Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol 2006, 6, 414-420.
13. Nowak JZ: Biosynthesis and characteristics of anti-inflammatory proresolving derivatives of omega-3 and omega-6 polyunsaturated fatty acids. Mil Pharm Med 2011, 3, 20-41.
14. Bazan NG: Neurotrphins induce neuroprotective signaling in the retinal pigment epithelial cell by activating the synthesis of the anti-inflammatory and anti-apoptotic neuroprotectin D1. Adv Exp Med Biol 2008, 613, 39-44.
15. Bazan NG: Neuroprotectin D1-mediated anti-inflammatory and survival signalling in stroke, retinal degenerations, and Alzheimer disease. J Lipid Res 2009, 50, 400-405.
16. Bazan NG, Molina MF, Gordon WC: Docosahexaenoic acid signalopidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. Annu Rev Nutr 2011, 31, 321-351.
17. Mukherjee PK, Marcheselli VL, Barreiro S, Hu J, Bok D, Bazan NG: Neurotrophins enhance retinal pigment epithelial cell survival through neuroprotectin D1 signaling. Proc Natl Acad Sci USA 2007, 104, 13152-13157.
18. Nowak JZ: Przeciwzapalne "prowygaszeniowe" pochodne wielonienasyconych kwasów tłuszczowych omega-3 i omega-6. Post Hig Med Dosw 2010, 64, 115-132.
19. Nowak JZ: Inflammation: course and role of PUFA-derived lipid mediators in the resolution of inflammatory reaction. Mil Pharm Med 2011, 1, 20-30.
20. Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, Oh SF, Spite Maresins M: Novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009, 16, 206, 15-23.
21. Catala A: Lipid peroxidation of membrane phospholipids generates hydroxyl-alkenals and oxidized phospholipids active in physiological and/or pathological conditions. Chem Phys Lipids 2009, 157, 1-11.
22. Esterbauer H: Cytotoxicity and genotoxicity of lipid-oxidation products. Am J Clin Nutr 1993, 57, 779-786.
23. Nowak JZ: W poszukiwaniu biomarkerów dla zwyrodnienia plamki zwiazanego z wiekiem (AMD). Mag Lek Okul 2009, 3, 132-143.
24. Nowak JZ: Oxidative stress, polyunsaturated fatty acids-derived oxidation products and bisretinoids as potential inducers of CNS diseases: focus on age-related macular degeneration. Pharmacol Rep 2013, 65, 288-304.
25. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts 2nd LJ: A series of prostaglandin f2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990, 87, 9383-9387.
26. Lawson JA, Kim S, Powell WS, FitzGerald GA, Rokach J: Oxidized derivatives of ω-3 fatty acids: identification of IPF3α-VI in human urine. J Lipid Res 2006, 47, 2515-2524.
27. Song WL, Paschos G, Fries S, Reilly MP, Yu Y, Rokach J, Chang CT, Patel P, Lawson JA, FitzGerald GA: Novel eicosapentaenoic acid-derived F3-isoprostanes as biomarkers of lipid peroxidation. J Biol Chem 2009, 284, 23636-23643.
28. Roberts LJ 2nd, Montine TJ, Markesbery WR, Tappert AR, Hardy P, Chemtob S, Dettbarn WD, Morrow JD: Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 1998, 273, 13605-13612.
29. Song WL, Lawson JA, Reilly D, Rokach J, Chang CT, Giasson B, Fitzgerald GA: Neurofurans, novel indices of oxidant stress derived from docosahexaenoic acid. J Biol Chem 2008, 283, 6-16.
30. Roberts LJ 2nd, Milne GL: Isoprostanes. J Lipid Res 2009, 50, 219-223.
31. Nowak JZ: Wielonienasycone kwasy tłuszczowe omega-3: aspekty biochemiczne, funkcjonalne i praktyczne. Farmakoter Psychiatr Neurol 2009, 3-4, 127-146.
32. Fliesler SJ, Anderson RE: Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res 1983, 22, 79-131.
33. Feller SE, Gawrisch K: Properties of docosahexaenoic-acid-containing lipids and their influence on the function of rhodopsin. Curr Opin Struct Biol 2005, 15, 416-422.
34. Gajewska-Meszaros S, Meszaros J: Ryby morskie i owoce morza: luksus czy konieczność. Ter Leki 2001, 2, 26, 31.
35. Committee on Diet and Health, Food and Nutrition Borad, National Research Council. Diet and Health: Implications for Reducing Chronic Disease Risk. National Academy Press, Washington 1989.
36. Drevon CA: Marine oils and their effects. Nutr Rev 1992, 50 (4 (Pt 2)), 38-45.
37. Chan JM, Gann PH, Giovannucci EL: Role of diet in prostate cancer development and progression. Clin Oncol 2005, 23, 8152-8160.
38. Strauss MH, Dorian P, Verma S: Fish oil supplementation and arrhythmias. JAMA 2005, 294, 2165-2166.
39. Banning M: The role of omega-3-fatty acids in the prevention of cardiac events. Br J Nurs 2005, 14, 503-508.
40. Mori TA: Omega-3 fatty acids and hypertension in humans. Clin Exp Pharmacol Physiol 2006, 33, 842-846.
41. McEwen BJ, Morel-Kopp MC, Chen W, Tofler GH, Ward CM: Effects of omega-3 polyunsaturated fatty acids on platelet function in healthy subjects and subjects with cardiovascular disease. Semin Thromb Hemost 2013, 39, 25-32.
42. Kristensen SD, Iversen AM, Schmidt EB: N-3 polyunsaturated fatty acids and coronary thrombosis. Lipids 2001, Suppl 36, 79-82.
43. Lee KW, Blann KD, Lip GY: Effects of omega-3 polyunsaturated fatty acids on plasma indices of thrombogenesis and inflammation in patients post-myocardial infarction. Thromb Res 2006, 118, 305-312.
44. Gajos G, Rostoff P, Undas A, Piwowarska W: Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study. J Am Coll Cardiol 2010, 55, 1671-1678.
45. Gajos G, Zalewski J, Rostoff P, Nessler J, Piwowarska W, Undas A: Reduced thrombin formation and altered fibrin clot properties induced by polyunsaturated omega-3 fatty acids on top of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (OMEGA-PCI clot). Arterioscler Thromb Vasc Biol 2011, 31, 1696-1702.
46. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC, Grimble RF: Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003, 361(9356), 477-485.
47. Eritsland J, Arnesen H, Grønseth K, Fjeld NB, Abdelnoor M: Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol 1996, 77, 31-36.
48. Leaf A: The electrophysiologic basis for the antiarrhythmic and anticonvulsant effects of n-3 polyunsaturated fatty acids: heart and brain. Lipids 2001, Suppl 36, 107-110.
49. Xiao YF, Gomez AM, Morgan JP, Lederer WJ, Leaf A: Suppression of voltage-gated L-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. Proc Natl Acad Sci USA 1997, 94, 4182-4187.
50. Salem N Jr, Litman B, Kim HY, Gawrisch K: Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 2001, 36, 945-959.
51. Ross BM, Seguin J, Sieswerda LE: Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis 2007, 18, 6-21.
52. Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D, Peet M, Keck PE Jr, Marangell LB, Richardson AJ, Lake J, Stoll AL: Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 2006, 67, 1954-1967.
53. Kris-Etherton PM, Hill AM: N-3 fatty acids: food or supplements? J Am Diet Assoc 2008, 108, 1125-1130.
54. Arterburn LM, Hall EB, Oken H: Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 2006, 83, Suppl 6, 1467-1476.
55. Arterburn LM, Oken HA, Bailey Hall E, Hamersley J, Kuratko CN, Hoffman JP: Algal-oil capsules and cooked salmon: nutritionally equivalent sources of docosahexaenoic acid. J Am Diet Assoc 2008, 108, 1204-1209.
56. National Heart Foundation of Australia. Position statement on Fish, fish oils, n-3 polyunsaturated fatty acids and cardiovascular health. Presented at AIFST conference July 2008. (online) Available at: www.heartfoundation.org.au/SiteCollectionDocuments/Fish-position-statement.pdf (Accessed September 17, 2014).
57. Gajos G, Zalewski J, Nessler J, Zmudka K, Undas A, Piwowarska W: Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism. Kardiol Pol 2012, 70, 439-445.
58. Larson MK, Ashmore JH, Harris KA, Vogelaar JL, Pottala JV, Sprehe M, Harris WS: Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb Haemost 2008, 100, 634-641.
59. Kris-Etherton PM, Harris WS, Appel LJ: Fish consumption, fish oil, omega-3fatty acids, and cardiovascular disease. Circulation 2002, 106, 2747-2757.
60. Krajowa Grupa Ekspertów. Rekomendacje Grupy Ekspertów dotyczaçe spozycia i suplementacji diety kwasami omega-3 w populacji ludzi dorosłych. Family Med Prim Care Rev 2007, 9, 175-177.
61. EFSA Panel on Dietetic Products, Nutrition and Allergies: Scientific opinion on the tolerable upper intake level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA J 2012, 10, 2815.